AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20938590 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for longer than six months
Number of subjects: 354
Study 20938590 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary interventions during the first year of life
Number of subjects: 354
Study 20938590 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing prevalence
Number of subjects: 354
Study 20938590 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma prevalence
Number of subjects: 354
Study 20938590 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy prevalence
Number of subjects: 354
Study 19077401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 19077401 — intervention group
Group type: COMPARATOR
Intervention: Apomorphine
Number of subjects: 0
Study 17154776 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses made via word-labeled buttons in the reverse Stroop task
Number of subjects: 0
Study 17154776 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses made via color-labeled buttons in the reverse Stroop task
Number of subjects: 0
Study 17154776 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from the 4 experiments
Number of subjects: 0
Study 14551489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy for 4 days
Number of subjects: 123
Study 14551489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 123
Study 11064970 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion from 0 degrees to 50 degrees and increased as tolerated (Group II)
Number of subjects: 120
Study 11064970 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion from 70 degrees to 110 degrees (Group III)
Number of subjects: 120
Study 11064970 — intervention group
Group type: COMPARATOR
Intervention: No continuous passive motion (Group I)
Number of subjects: 120
Study 8698446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (1.9 MJ/d) for 2 weeks
Number of subjects: 51
Study 8698446 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (6.3 to 8.4 MJ/d) for 4 weeks
Number of subjects: 51
Study 1450707 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 60
Study 1450707 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 6399463 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal biofeedback
Number of subjects: 42
Study 6399463 — intervention group
Group type: COMPARATOR
Intervention: Abbreviated progressive relaxation
Number of subjects: 42
Study 29391379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit-crew device training
Number of subjects: 60
Study 29391379 — intervention group
Group type: COMPARATOR
Intervention: Standard mechanical chest compression device training
Number of subjects: 60
Study 24700342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) pretreatment for 4 weeks
Number of subjects: 54
Study 24700342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) pretreatment
Number of subjects: 54
Study 24700342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RBV pretreatment)
Number of subjects: 54
Study 24351147 — intervention group
Group type: EXPERIMENTAL
Intervention: Superelastic nickel-titanium wire
Number of subjects: 36
Study 24351147 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistranded steel wire
Number of subjects: 36
Study 24351147 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel wire
Number of subjects: 36
Study 19713248 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX (oxaliplatin 65 mg/m2 i.v. days 1 and 8 and capecitabine 1000 mg/m2 orally b.i.d. days 1-14; q21d)
Number of subjects: 94
Study 19713248 — intervention group
Group type: COMPARATOR
Intervention: CAPIRI (irinotecan 80 mg/m2 i.v. days 1 and 8 and capecitabine 1000 mg/m2 orally b.i.d. days 1-14; q21d)
Number of subjects: 94
Study 19713248 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX
Number of subjects: 94
Study 19713248 — intervention group
Group type: COMPARATOR
Intervention: CAPIRI
Number of subjects: 94
Study 18724827 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial techniques (suboccipital muscle technique, compression of fourth intracranial ventricle, deep cervical fascia technique)
Number of subjects: 41
Study 18724827 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial techniques
Number of subjects: 41
Study 18724827 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting position)
Number of subjects: 41
Study 16622803 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincubation of oocytes in follicular fluid for 3 hours after oocyte retrieval
Number of subjects: 0
Study 16622803 — intervention group
Group type: COMPARATOR
Intervention: Control oocytes preincubated in normal IVF culture medium
Number of subjects: 0
Study 12670840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 0.125 mg
Number of subjects: 10
Study 12670840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 1.25 mg
Number of subjects: 10
Study 12670840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 12.5 mg
Number of subjects: 10
Study 12670840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 125 mg
Number of subjects: 10
Study 12670840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 1,250 mg
Number of subjects: 10
Study 12670840 — intervention group
Group type: COMPARATOR
Intervention: Control (no STS)
Number of subjects: 10
Study 10611148 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral baclofen
Number of subjects: 20
Study 10611148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9360033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises combined with electrical stimulation of pelvic floor (six sessions).
Number of subjects: 80
Study 9360033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 80
Study 1326584 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of varicella-zoster virus (VZV) DNA using PCR in oropharyngeal epithelium
Number of subjects: 0
Study 1326584 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of varicella-zoster virus (VZV) DNA using PCR in peripheral blood leukocytes
Number of subjects: 0
Study 1326584 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR detection of VZV DNA in oropharynx and blood
Number of subjects: 0
Study 3895210 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 113
Study 3895210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 30862500 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02% QD (PM)
Number of subjects: 372
Study 30862500 — intervention group
Group type: COMPARATOR
Intervention: Timolol ophthalmic solution 0.5% BID
Number of subjects: 372
Study 30862500 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil QD
Number of subjects: 372
Study 30862500 — intervention group
Group type: COMPARATOR
Intervention: Timolol BID
Number of subjects: 372
Study 28807071 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BVM with external handle
Number of subjects: 70
Study 28807071 — intervention group
Group type: COMPARATOR
Intervention: Standard BVM
Number of subjects: 70
Study 23552589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1ug/kg administered intravenously over 10 minutes before intubation (group D)
Number of subjects: 60
Study 23552589 — intervention group
Group type: COMPARATOR
Intervention: Normal saline administered (group C)
Number of subjects: 60
Study 20708715 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐Based Behavioral Group Intervention
Number of subjects: 240
Study 20708715 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Only Behavioral Group Intervention
Number of subjects: 240
Study 20708715 — intervention group
Group type: COMPARATOR
Intervention: Education Control Condition
Number of subjects: 240
Study 19787151 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg daily)
Number of subjects: 64
Study 19787151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16782924 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR positive patients (n = 620)
Number of subjects: 1446
Study 16782924 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of more than one RT‐PCR marker in peripheral blood (PBMC) from 820 patients
Number of subjects: 1446
Study 16782924 — intervention group
Group type: COMPARATOR
Intervention: RT‐PCR analysis on sentinel lymph nodes (SLNs) and PBMCs
Number of subjects: 1446
Study 15579735 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg octreotide long-acting repeatable (LAR) every 4 wk for 16 wk
Number of subjects: 50
Study 15579735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15579735 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg octreotide LAR
Number of subjects: 50
Study 15579735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LAR and placebo)
Number of subjects: 50
Study 11463593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT) mechanical ventilation strategy (6 ml/kg)
Number of subjects: 902
Study 9534750 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic interferon alpha 2b (IFN‐alpha)
Number of subjects: 92
Study 9534750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 9534750 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic phase serum IL‐2
Number of subjects: 92
Study 7712001 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Quality Management (TQM)
Number of subjects: 0
Study 7712001 — intervention group
Group type: EXPERIMENTAL
Intervention: Deming adherents
Number of subjects: 0
Study 7712001 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclectic choices
Number of subjects: 0
Study 7712001 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement techniques
Number of subjects: 0
Study 7712001 — intervention group
Group type: EXPERIMENTAL
Intervention: Top management support
Number of subjects: 0
Study 7712001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician support for quality initiatives
Number of subjects: 0
Study 7712001 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Quality Management (TQM) maturity
Number of subjects: 0
Study 2853047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran (17.1 g/d)
Number of subjects: 8
Study 2853047 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (15.0 g/d)
Number of subjects: 8
Study 2853047 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 8
Study 30269534 — intervention group
Group type: EXPERIMENTAL
Intervention: Online individualised intervention comprising e-learning and decision support e-tools
Number of subjects: 27
Study 30269534 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for care home staff
Number of subjects: 27
Study 30269534 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning and e-tools
Number of subjects: 27
Study 29389474 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg rosemary twice daily for one month
Number of subjects: 68
Study 29389474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26821664 — intervention group
Group type: EXPERIMENTAL
Intervention: 6×1 hour practical course with systematic feedback (27 students)
Number of subjects: 48
Study 26821664 — intervention group
Group type: COMPARATOR
Intervention: Regular clerkship activities only (21 students)
Number of subjects: 48
Study 24385519 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based training program
Number of subjects: 317
Study 24385519 — intervention group
Group type: COMPARATOR
Intervention: Existing flat-text e-learning program
Number of subjects: 317
Study 23025690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU/dose, given twice daily for 3 days)
Number of subjects: 11
Study 23025690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 11
Study 23025690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21130361 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Acupuncture (EA)
Number of subjects: 50
Study 21130361 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 50
Study 21130361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 50
Study 18438562 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac with pressure application before light-curing
Number of subjects: 120
Study 18438562 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi-Purpose with pressure application before light-curing
Number of subjects: 120
Study 18438562 — intervention group
Group type: COMPARATOR
Intervention: Syntac without pressure application
Number of subjects: 120
Study 18438562 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Multi-Purpose without pressure application
Number of subjects: 120
Study 16391299 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (60 microg/kg/d)
Number of subjects: 212
Study 14552407 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 0
Study 14552407 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study 10999790 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% carbohydrate diet
Number of subjects: 12
Study 10999790 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% carbohydrate diet
Number of subjects: 12
Study 8625660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (bud), 1,600 micrograms/d
Number of subjects: 58
Study 8625660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 1,600 micrograms/d, plus oral prednisolone, 5 micrograms/d (bud + pred)
Number of subjects: 58
Study 8625660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plac)
Number of subjects: 58
Study 8625660 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study 1428609 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR polymer implant
Number of subjects: 15
Study 1428609 — intervention group
Group type: COMPARATOR
Intervention: Control site (surgically debrided without implant)
Number of subjects: 15
Study 6307772 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ranitidine twice daily
Number of subjects: 82
Study 6307772 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine twice daily
Number of subjects: 82
Study 31601493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel and carboplatin
Number of subjects: 193
Study 31601493 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 193
Study 28770631 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-based female empowerment curriculum
Number of subjects: 801
Study 28770631 — intervention group
Group type: COMPARATOR
Intervention: Dose-matched science and technology female leadership curriculum
Number of subjects: 801
Study 26603297 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA, area under the curve = 5) plus pemetrexed (PEM, 500 mg/m²) followed by maintenance pemetrexed (PEM)
Number of subjects: 34
Study 24676290 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Number of subjects: 200
Study 24676290 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 200
Study 24676290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both polyethylene glycol and lactulose
Number of subjects: 200
Study 20633419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (20 Hz) deep transcranial magnetic stimulation (DTMS) over the prefrontal cortex
Number of subjects: 65
Study 20633419 — intervention group
Group type: COMPARATOR
Intervention: Low stimulation intensity DTMS
Number of subjects: 65
Study 20633419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity DTMS
Number of subjects: 65
Study 20633419 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity DTMS
Number of subjects: 65
Study 20633419 — intervention group
Group type: EXPERIMENTAL
Intervention: DTMS treatment
Number of subjects: 65
Study 14766684 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mL clear liquid two hours before surgery
Number of subjects: 126
Study 14766684 — intervention group
Group type: COMPARATOR
Intervention: Fasting (no fluid intake)
Number of subjects: 126
Study 11308062 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report methods for assessing disability in mobility
Number of subjects: 186
Study 11308062 — intervention group
Group type: COMPARATOR
Intervention: Observational method for assessing disability in mobility
Number of subjects: 186
Study 11308062 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report methods and observational method
Number of subjects: 186
Study 9692616 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) therapy for 8 months
Number of subjects: 15
Study 9692616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin treatment for 14 days
Number of subjects: 15
Study 9692616 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls and untreated hemodialysis patients
Number of subjects: 15
Study 7940423 — intervention group
Group type: EXPERIMENTAL
Intervention: Brasfield chest radiograph score
Number of subjects: 62
Study 7940423 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH chest radiograph score
Number of subjects: 62
Study 7940423 — intervention group
Group type: EXPERIMENTAL
Intervention: RCH chest radiograph score
Number of subjects: 62
Study 3078903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 200
Study 3078903 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 200
Study 11772800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg before surgery
Number of subjects: 60
Study 11772800 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib 50 mg after surgery
Number of subjects: 60
Study 11772800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31353040 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle behavioral intervention over 3 years
Number of subjects: 605
Study 29846189 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 200
Study 29846189 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-derived MVPA
Number of subjects: 200
Study 29846189 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation (socio-ecological correlate)
Number of subjects: 200
Study 29846189 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood aesthetics (socio-ecological correlate)
Number of subjects: 200
Study 28074750 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant pharmacist services with academic detailing, medication monitoring system alerts, and structured recommendations for ADE management
Number of subjects: 0
Study 28074750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 0
Study 24742498 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC AZI/AML 20/5 mg
Number of subjects: 603
Study 24742498 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC AZI/AML 20/2.5 mg
Number of subjects: 603
Study 24742498 — intervention group
Group type: COMPARATOR
Intervention: AZI 20 mg
Number of subjects: 603
Study 24742498 — intervention group
Group type: COMPARATOR
Intervention: AML 5 mg
Number of subjects: 603
Study 24742498 — intervention group
Group type: COMPARATOR
Intervention: AML 2.5 mg
Number of subjects: 603
Study 21614479 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + NDL at 1 W
Number of subjects: 20
Study 21614479 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 20
Study 19580461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg per week of risedronate
Number of subjects: 53
Study 19580461 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg per week of risedronate
Number of subjects: 53
Study 19580461 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg per week of risedronate
Number of subjects: 53
Study 19580461 — intervention group
Group type: EXPERIMENTAL
Intervention: risedronate (all doses)
Number of subjects: 53
Study 19580461 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2 mg/kg per week of risedronate
Number of subjects: 53
Study 19091088 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Constraint-Induced Movement Therapy (modified CIMT) for 3 weeks
Number of subjects: 180
Study 19091088 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered Neuro-Muscular Stimulation (EMG-NMS) for 3 weeks
Number of subjects: 180
Study 19091088 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 180
Study 15777325 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively loaded implants
Number of subjects: 20
Study 15777325 — intervention group
Group type: COMPARATOR
Intervention: Conventionally loaded implants
Number of subjects: 20
Study 12501879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren 200 mg BID
Number of subjects: 802
Study 12501879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren 400 mg BID
Number of subjects: 802
Study 12501879 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 875/125 mg BID
Number of subjects: 802
Study 10710759 — intervention group
Group type: EXPERIMENTAL
Intervention: KR-withdrawal early in practice
Number of subjects: 120
Study 10710759 — intervention group
Group type: EXPERIMENTAL
Intervention: KR-withdrawal later in practice
Number of subjects: 120
Study 10710759 — intervention group
Group type: EXPERIMENTAL
Intervention: KR-withdrawal
Number of subjects: 120
Study 8551535 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate and Lactobacillus acidophilus
Number of subjects: 27
Study 8551535 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate only
Number of subjects: 27
Study 1775610 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral-nondominant ECT (UND)
Number of subjects: 0